An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children

Trial Profile

An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs GSK 2321138A (Primary) ; Hepatitis A vaccine inactivated; Pneumococcal 7-valent CRM197 vaccine conjugate; Varicella zoster virus vaccine live
  • Indications Chickenpox; Hepatitis A; Hepatitis B; Influenza virus infections; Pneumococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Mar 2017 According to a GlaxoSmithKline media release, data from this study will be presented at upcomming annual meeting of European Society for Paediatric Infectious Diseases.
    • 15 Mar 2017 According to a GlaxoSmithKline media release, company submitted a supplemental Biologics License Application (sBLA) to the US FDA to seek an expanded indication for the quadrivalent influenza vaccine for children six months through 35 months of age, based on data from this and other two two supportive studies.
    • 18 Jan 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top